» Articles » PMID: 36175480

Interruption of Aberrant Chromatin Looping is Required for Regenerating RB1 Function and Suppressing Tumorigenesis

Overview
Journal Commun Biol
Specialty Biology
Date 2022 Sep 29
PMID 36175480
Authors
Affiliations
Soon will be listed here.
Abstract

RB transcriptional corepressor 1 (RB1) is a critical regulatory gene in physiological and pathological processes. Genetic mutation is considered to be the main cause of RB1 inactivation. However, accumulating evidence has shown that not all RB1 dysfunction is triggered by gene mutations, and the additional mechanism underlying RB1 dysfunction remains unclear. Here, we firstly reveal that a CCCTC binding factor (CTCF) mediated intrachromosomal looping served as a regulatory inducer to inactivate RB1. Once the core genomic fragment was deleted by Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 (CRISPR/Cas9), this intrachromosomal looping was disrupted. After the open of chromatin, Enhancer of Zeste Homolog 2 (EZH2) was released and decreased the level of Tri-Methyl-Histone H3 Lys27 (H3K27me3) at the RB1 promoter, which substantially restored the expression of RB protein (pRB) and inhibited tumorigenesis. In addition, targeted correction of abnormal RB1 looping using the small-molecule compound GSK503 efficiently restored RB1 transcription and suppressed tumorigenesis. Our study reveals an alternative transcriptional mechanism underlying RB1 dysfunction independent of gene mutation, and advancing the discovery of potential therapeutic chemicals based on aberrant chromatin looping.

Citing Articles

Parkinson's disease-associated alterations in DNA methylation and hydroxymethylation in human brain.

Choza J, Virani M, Kuhn N, Adams M, Kochmanski J, Bernstein A bioRxiv. 2025; .

PMID: 39975085 PMC: 11838189. DOI: 10.1101/2024.05.21.595193.


Prohibitin 2 orchestrates long noncoding RNA and gene transcription to accelerate tumorigenesis.

Ding T, Xu H, Zhang X, Yang F, Zhang J, Shi Y Nat Commun. 2024; 15(1):8385.

PMID: 39333493 PMC: 11436821. DOI: 10.1038/s41467-024-52425-z.


Therapeutic potential of tLyp-1-EV-shCTCF in inhibiting liver cancer stem cell self-renewal and immune escape via SALL3 modulation in hepatocellular carcinoma.

Zhu H, Xie Z Transl Oncol. 2024; 49:102048.

PMID: 39186862 PMC: 11388803. DOI: 10.1016/j.tranon.2024.102048.


Study on the Effect of EZH2 Inhibitor Combined with TIGIT Monoclonal Antibody against Multiple Myeloma Cells.

Liu Z, Jia Y, Yang C, Liu H, Shen H, Wang H Int J Mol Sci. 2023; 24(10).

PMID: 37239949 PMC: 10218613. DOI: 10.3390/ijms24108603.

References
1.
Levine A, Oren M . The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009; 9(10):749-58. PMC: 2771725. DOI: 10.1038/nrc2723. View

2.
Zhang J, Benavente C, McEvoy J, Flores-Otero J, Ding L, Chen X . A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012; 481(7381):329-34. PMC: 3289956. DOI: 10.1038/nature10733. View

3.
Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M . Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature. 2004; 430(7001):797-802. DOI: 10.1038/nature02820. View

4.
Hansen A, Pustova I, Cattoglio C, Tjian R, Darzacq X . CTCF and cohesin regulate chromatin loop stability with distinct dynamics. Elife. 2017; 6. PMC: 5446243. DOI: 10.7554/eLife.25776. View

5.
Jager R, Migliorini G, Henrion M, Kandaswamy R, Speedy H, Heindl A . Capture Hi-C identifies the chromatin interactome of colorectal cancer risk loci. Nat Commun. 2015; 6:6178. PMC: 4346635. DOI: 10.1038/ncomms7178. View